Cost-effectiveness of pre-operative Staphylococcus aureus screening and decolonization

Infect Control Hosp Epidemiol. 2018 Nov;39(11):1340-1346. doi: 10.1017/ice.2018.228. Epub 2018 Sep 20.

Abstract

Objective: We developed a decision analytic model to evaluate the impact of a preoperative Staphylococcus aureus decolonization bundle on surgical site infections (SSIs), health-care-associated costs (HCACs), and deaths due to SSI.

Methods: Our model population comprised US adults undergoing elective surgery. We evaluated 3 self-administered preoperative strategies: (1) the standard of care (SOC) consisting of 2 disinfectant soap showers; (2) the "test-and-treat" strategy consisting of the decolonization bundle including chlorhexidine gluconate (CHG) soap, CHG mouth rinse, and mupirocin nasal ointment for 5 days) if S. aureus was found at any of 4 screened sites (nasal, throat, axillary, perianal area), otherwise the SOC; and (3) the "treat-all" strategy consisting of the decolonization bundle for all patients, without S. aureus screening. Model parameters were derived primarily from a randomized controlled trial that measured the efficacy of the decolonization bundle for eradicating S. aureus.

Results: Under base-case assumptions, the treat-all strategy yielded the fewest SSIs and the lowest HCACs, followed by the test-and-treat strategy. In contrast, the SOC yielded the most SSIs and the highest HCACs. Consequently, relative to the SOC, the average savings per operation was $217 for the treat-all strategy and $123 for the test-and-treat strategy, and the average savings per per SSI prevented was $21,929 for the treat-all strategy and $15,166 for the test-and-treat strategy. All strategies were sensitive to the probability of acquiring an SSI and the increased risk if SSI if the patient was colonized with SA.

Conclusion: We predict that the treat-all strategy would be the most effective and cost-saving strategy for preventing SSIs. However, because this strategy might select more extensively for mupirocin-resistant S. aureus and cause more medication adverse effects than the test-and-treat approach or the SOC, additional studies are needed to define its comparative benefits and harms.

Publication types

  • Research Support, N.I.H., Extramural
  • Research Support, Non-U.S. Gov't
  • Research Support, U.S. Gov't, Non-P.H.S.
  • Research Support, U.S. Gov't, P.H.S.

MeSH terms

  • Administration, Intranasal
  • Anti-Bacterial Agents / administration & dosage*
  • Anti-Bacterial Agents / economics
  • Chlorhexidine / administration & dosage
  • Chlorhexidine / analogs & derivatives*
  • Chlorhexidine / economics
  • Cost-Benefit Analysis
  • Disinfection / economics
  • Disinfection / methods*
  • Humans
  • Models, Economic*
  • Mupirocin / administration & dosage*
  • Mupirocin / economics
  • Staphylococcal Infections / diagnosis
  • Staphylococcal Infections / prevention & control
  • Staphylococcus aureus / isolation & purification
  • Surgical Wound Infection / economics
  • Surgical Wound Infection / microbiology
  • Surgical Wound Infection / prevention & control*
  • United States

Substances

  • Anti-Bacterial Agents
  • Mupirocin
  • chlorhexidine gluconate
  • Chlorhexidine